Search clinical trials for: Smoothened inhibitor

Total 67894 results

Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant Solid Neoplasm | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma | Clinical... and other conditions

United States
St. Jude Children's Research Hospital
Novartis Pharmaceuticals

Completed

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Glioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Central Nervous System Neoplasms | Brain Cancer | Brain Tumor | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Pineoblastoma | Recurrent Medulloblastoma | CNS Tumor | Pediatric... and other conditions

United States
Endeavor Biomedicines, Inc.

Active, not recruiting

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Solid Tumors With PTCH1 Loss-of-function Mutations

United States
Endeavor Biomedicines, Inc.

Completed

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

Idiopathic Pulmonary Fibrosis

Australia
Mayo Clinic
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
Novartis Pharmaceuticals

Completed

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Medulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor Cancers

Spain, Switzerland, United Kingdom, United States
Novartis Pharmaceuticals

Completed

An East Asian Study of LDE225

Medulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor Cancers

Taiwan, Hong Kong, Japan
Novartis Pharmaceuticals

Completed

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Metastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...

Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Mayo Clinic
National Cancer Institute (NCI)

Completed

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Childhood Acute Myeloid Leukemia and other conditions

United States
Pfizer

Terminated

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

United States, Japan
Novartis Pharmaceuticals

Withdrawn

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Basal Cell Carcinoma

Greece, Switzerland, Germany, United Kingdom, Belgium, Canada, Czechia, Finland, Italy, Spain
Bristol-Myers Squibb

Terminated

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Leukemia

France, United States, Spain, Poland, Finland, Argentina, Canada, Belgium
SCRI Development Innovations, LLC
Novartis

Terminated

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Anne Chang
Novartis

Completed

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

Basal Cell Carcinoma

United States
Bristol-Myers Squibb

Completed

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Leukemia

United States, Canada, Finland, Italy, United Kingdom, France, Germany
Ain Shams University

Recruiting

Clinical Outcome of Vinpocetine in Diabetic Nephropathy

Diabetic Kidney Disease | Diabetic Nephropathies

Egypt
Diakonhjemmet Hospital
Karolinska University Hospital; Medical University of Vienna; Oslo University... and other collaborators

Not yet recruiting

Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM) (RA-DRUM)

Rheumatoid Arthritis

Austria, Sweden, Norway, United Kingdom
Applied Science & Performance Institute

Recruiting

Acute Effects of PLT Health Solutions zümXR Extended-Release Caffeine

Cognitive Change | Mood | Caffeine | Mood Change

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma | Thyroid Gland Oncocytic Carcinoma

United States
University of California, San Francisco
Johns Hopkins University

Not yet recruiting

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)

Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Tuberculosis, MDR

Peru, Vietnam, Moldova, Republic of, Mongolia, Pakistan, Philippines, South Africa
Xijing Hospital

Recruiting

Preoperative Adjuvant SOX Plus PL-1 Antibody and FLOT Plus PD-1 Antibody for Locally Advanced dMMR Gastric Cancer

Gastric Cancer | Chemotherapeutic Toxicity | Immune-related Adverse Event

China
Incyte Corporation

Not yet recruiting

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

Healthy Participants
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Waldenström's Macroglobulinemia (WM)

Italy
Fudan University

Not yet recruiting

Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab

China
Ruijin Hospital

Not yet recruiting

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Diffuse Large B-Cell Lymphoma
Fujian Cancer Hospital

Not yet recruiting

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Leptomeningeal Metastasis

China
Medical University of Vienna

Recruiting

Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support (CASUAL-ECMO)

Respiratory Insufficiency | Bleeding | Thromboembolism | Circulatory Failure

Austria
Astellas Pharma Global Development, Inc.

Not yet recruiting

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Hot Flashes
Regina Elena Cancer Institute

Recruiting

Low Intensity Shock Wave Therapy in the Rehabilitation Treatment of Erectile Dysfunction After Robotic Radical Prostatectomy.

Erectile Dysfunction

Italy
Yinyi(Liaoning) Biotech Co., Ltd.

Not yet recruiting

Bingo Drug-eluting Balloon Versus a Drug-eluting Stent for Coronary Bifurcation Lesions

Coronary Artery Disease
Anhui Provincial Hospital

Recruiting

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Cytomegalovirus Infection Reactivation

China
University of Palermo

Not yet recruiting

SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF (DAPA-TONIC)

Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Diabetes Type 2 | Heart Failure Acute
International Bio service

Not yet recruiting

Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions

Healthy Volunteer | Bioequivalence Study | Dabigatran
Australasian Gastro-Intestinal Trials Group
AstraZeneca; Wayne Elphinstone Research Fund

Not yet recruiting

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Cholangiocarcinoma

Australia
Hunan Province Tumor Hospital
Hunan Cancer Hospital

Recruiting

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases (EPIC)

Non-Small Cell Lung Cancer

China
XIANG YANQUN

Not yet recruiting

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

Nasopharyngeal Carcinoma
Hoffmann-La Roche
Shanghai Roche Pharmaceutical Co., Ltd

Recruiting

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Diabetic Macular Edema | Retinal Vein Occlusion | Neovascular Age-related Macular Degeneration

China
West China Hospital

Not yet recruiting

Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

Cholangiocarcinoma
Tang-Du Hospital

Not yet recruiting

Baricitinib for the Lung Injury Following Spontaneous SAH (BLISS)

Spontaneous Subarachnoid Hemorrhage
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma
M.D. Anderson Cancer Center
Incyte Corporation

Not yet recruiting

Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Advanced Cholangiocarcinoma | FGFR2 Fusion

United States
Mayo Clinic

Recruiting

Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

Malignant Solid Neoplasm | Melanoma | Renal Cell Carcinoma | Lung Non-Small Cell Carcinoma | Urothelial Carcinoma | Lung Small Cell Carcinoma

United States
EicOsis Human Health Inc.

Recruiting

Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury

Neuropathic Pain | Spinal Cord Injuries

United States
Dana-Farber Cancer Institute
Johns Hopkins University; Translational Breast Cancer Research Consortium

Not yet recruiting

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Stage IV Breast Cancer | Breast Cancer Female | Breast Cancer Metastatic | Estrogen Receptor-positive Breast Cancer

United States
Zhejiang Cancer Hospital

Not yet recruiting

Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer

Gastric Cancer

China
Beijing Tongren Hospital
The First Affiliated Hospital with Nanjing Medical University

Not yet recruiting

Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis

Reversal of Neuromuscular Blockade

China
Wuhan Union Hospital, China

Recruiting

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

Rhinitis, Allergic

China
First Affiliated Hospital of Zhejiang University
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Recruiting

Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Myeloid Malignancy | Relapsed/Refractory Acute Myeloid Leukaemia

China

Search clinical trials for: Smoothened inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations